Evidence map›Paper›PMID 27492817›Full record

ArticlePediatrics2016

Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children.

Natalie Pica, Florence Bourgeois

Abstract read
In one paragraph

Article in Pediatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Time to publication for results of clinical trials.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Moving toward precision communication in pediatric oncology clinical trials: An outline of a conceptual framework to support caregiver decision-making.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Using Simulation to Optimize the Design of Adaptive Clinical Trials.Journal of the American Society of Nephrology : JASN · 2025
    Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Natalie PicaDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts; Boston Combined Residency Program, Boston Children's Hospital and Boston Medical Center, Boston, Massachusetts; and.
Florence BourgeoisDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts; Division of Emergency Medicine and Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts florence.bourgeois@childrens.harvard.edu.

Funding

Establishing Surveillance of the Pediatric Evidence Base for Drug TherapyR21HD072382 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI BOURGEOIS, FLORENCE, MANDL, KENNETH D. · 2012 to 2013
$479k
NICHD NIH HHS R21 HD072382
6 · The paper itself

Abstract

backgroundTrial discontinuation and nonpublication represent potential waste in research resources and lead to compromises in medical evidence. Pediatric trials may be particularly vulnerable to these outcomes given the challenges encountered in conducting trials in children. We aimed to determine the prevalence of discontinuation and nonpublication of randomized clinical trials (RCTs) conducted in pediatric populations.

methodsRetrospective, cross-sectional study of pediatric RCTs registered in ClinicalTrials.gov from 2008 to 2010. Data were collected from the registry and associated publications identified (final search on September 1, 2015).

resultsOf 559 trials, 104 (19%) were discontinued early, accounting for an estimated 8369 pediatric participants. Difficulty with patient accrual (37%) was the most commonly cited reason for discontinuation. Trials were less likely to be discontinued if they were funded by industry compared with academic institutions (odds ratio [OR] 0.46, 95% confidence interval [CI] 0.27-0.77). Of the 455 completed trials, 136 (30%) were not published, representing 69 165 pediatric participants. Forty-two unpublished trials posted results on ClinicalTrials.gov. Trials funded by industry were more than twice as likely to result in nonpublication at 24 and 36 months (OR 2.21, 95% CI 1.35-3.64; OR 3.12, 95% CI 1.6-6.08, respectively) and had a longer mean time to publication compared with trials sponsored by academia (33 vs 24 months, P < .001).

conclusionsIn this sample of pediatric RCTs, discontinuation and nonpublication were common, with thousands of children exposed to interventions that did not lead to informative or published findings. Trial funding source was an important determinant of these outcomes, with both academic and industry sponsors contributing to inefficiencies.

Indexed as

AdolescentChildChild, PreschoolCross-Sectional StudiesEarly Termination of Clinical TrialsFemaleHumansInfantInfant, NewbornLogistic ModelsMalePublishingRandomized Controlled Trials as TopicRegistriesResearch Support as TopicRetrospective Studies

Identifiers

PMID27492817
PMCPMC5005019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.